{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T20:23:20Z","timestamp":1776025400361,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2014,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The epidermal growth factor receptor family is expressed in breast cancer, and agents targeting this pathway have single agent effects (e.g. traztuzumab). Development of resistance may be due to the presence of alternative pathways, particularly activation of the PI3K\/Akt\/MTOR pathway. We have therefore examined the effect of inhibitors of this pathway (ZSTK474 and sirolimus) in combination with the epidermal growth factor (EGFR) inhibitors erlotinib and gefitinib in breast MCF10a isogenic cell lines with EGFR, BRAF, AKT, and PI3K mutations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>PI3K mutation conferred increased activity of EGFR inhibitors against MCF10a cells in comparison with the parental cell line and other mutations studied. Combination of EGFR inhibitors with either the PI3K inhibitor ZSTK474 or the MTOR inhibitor sirolimus showed increased activity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These results are encouraging for the use of combinations targeting the PI3K and EGFR pathway simultaneously.<\/jats:p><\/jats:sec>","DOI":"10.1186\/1756-0500-7-397","type":"journal-article","created":{"date-parts":[[2014,6,25]],"date-time":"2014-06-25T21:03:12Z","timestamp":1403730192000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Activity of EGFR, mTOR and PI3K inhibitors in an isogenic breast cell line model"],"prefix":"10.1186","volume":"7","author":[{"given":"Sharon","family":"Glaysher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise M","family":"Bolton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Penny","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Torrance","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian A","family":"Cree","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,6,25]]},"reference":[{"issue":"6","key":"2921_CR1","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1007\/s11605-011-1504-z","volume":"15","author":"L Yang","year":"2011","unstructured":"Yang L, Li J, Ran L, Pan F, Zhao X, Ding Z, Chen Y, Peng Q, Liang H: Phosphorylated insulin-like growth factor 1 receptor is implicated in resistance to the cytostatic effect of gefitinib in colorectal cancer cells. J Gastrointest Surg. 2011, 15 (6): 942-957.","journal-title":"J Gastrointest Surg"},{"issue":"5","key":"2921_CR2","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1158\/0008-5472.CAN-09-3326","volume":"70","author":"A Jain","year":"2010","unstructured":"Jain A, Penuel E, Mink S, Schmidt J, Hodge A, Favero K, Tindell C, Agus DB: HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation. Cancer Res. 2010, 70 (5): 1989-1999.","journal-title":"Cancer Res"},{"issue":"22","key":"2921_CR3","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1038\/onc.2010.626","volume":"30","author":"V Serra","year":"2011","unstructured":"Serra V, Scaltriti M, Prudkin L, Eichhorn PJ, Ibrahim YH, Chandarlapaty S, Markman B, Rodriguez O, Guzman M, Rodriguez S, Gili M, Russillo M, Parra JL, Singh S, Arribas J, Rosen N, Baselga J: PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene. 2011, 30 (22): 2547-2557.","journal-title":"Oncogene"},{"issue":"4","key":"2921_CR4","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ccr.2007.08.030","volume":"12","author":"K Berns","year":"2007","unstructured":"Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R: A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007, 12 (4): 395-402.","journal-title":"Cancer Cell"},{"issue":"19","key":"2921_CR5","doi-asserted-by":"publisher","first-page":"8022","DOI":"10.1158\/0008-5472.CAN-08-1385","volume":"68","author":"V Serra","year":"2008","unstructured":"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J: NVP-BEZ235, a dual PI3K\/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 2008, 68 (19): 8022-8030.","journal-title":"Cancer Res"},{"issue":"2","key":"2921_CR6","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s10549-011-1572-5","volume":"128","author":"E Razis","year":"2011","unstructured":"Razis E, Bobos M, Kotoula V, Eleftheraki AG, Kalofonos HP, Pavlakis K, Papakostas P, Aravantinos G, Rigakos G, Efstratiou I, Petraki K, Bafaloukos D, Kostopoulos I, Pectasides D, Kalogeras KT, Skarlos D, Fountzilas G: Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast Cancer Res Treat. 2011, 128 (2): 447-456.","journal-title":"Breast Cancer Res Treat"},{"key":"2921_CR7","doi-asserted-by":"publisher","first-page":"415170","DOI":"10.1155\/2012\/415170","volume":"2012","author":"AL Wong","year":"2012","unstructured":"Wong AL, Lee SC: Mechanisms of resistance to trastuzumab and novel therapeutic strategies in HER2-positive breast cancer. Int J Breast Cancer. 2012, 2012: 415170-","journal-title":"Int J Breast Cancer"},{"issue":"7126","key":"2921_CR8","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nature05474","volume":"445","author":"NV Sergina","year":"2007","unstructured":"Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM: Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 2007, 445 (7126): 437-441.","journal-title":"Nature"},{"issue":"24","key":"2921_CR9","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1093\/jnci\/93.24.1852","volume":"93","author":"Y Lu","year":"2001","unstructured":"Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M: Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst. 2001, 93 (24): 1852-1857.","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"2921_CR10","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1172\/JCI37539","volume":"120","author":"F Di Nicolantonio","year":"2010","unstructured":"Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T, Russo M, Cancelliere C, Zecchin D, Mazzucchelli L, Sasazuki T, Shirasawa S, Geuna M, Frattini M, Baselga J, Gallicchio M, Biffo S, Bardelli A: Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest. 2010, 120 (8): 2858-2866.","journal-title":"J Clin Invest"},{"issue":"20","key":"2921_CR11","doi-asserted-by":"publisher","first-page":"7105","DOI":"10.1021\/jm200688y","volume":"54","author":"GW Rewcastle","year":"2011","unstructured":"Rewcastle GW, Gamage SA, Flanagan JU, Frederick R, Denny WA, Baguley BC, Kestell P, Singh R, Kendall JD, Marshall ES, Lill CL, Lee WJ, Kolekar S, Buchanan CM, Jamieson SM, Shepherd PR: Synthesis and biological evaluation of novel analogues of the pan class I Phosphatidylinositol 3-Kinase (PI3K) Inhibitor 2-(Difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimi dazole (ZSTK474). J Med Chem. 2011, 54 (20): 7105-7126.","journal-title":"J Med Chem"},{"issue":"3","key":"2921_CR12","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/BF01806507","volume":"37","author":"MJ Pilat","year":"1996","unstructured":"Pilat MJ, Christman JK, Brooks SC: Characterization of the estrogen receptor transfected MCF10A breast cell line 139B6. Breast Cancer Res Treat. 1996, 37 (3): 253-266.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"2921_CR13","doi-asserted-by":"publisher","first-page":"e9201","DOI":"10.1371\/journal.pone.0009201","volume":"5","author":"M Kadota","year":"2010","unstructured":"Kadota M, Yang HH, Gomez B, Sato M, Clifford RJ, Meerzaman D, Dunn BK, Wakefield LM, Lee MP: Delineating genetic alterations for tumor progression in the MCF10A series of breast cancer cell lines. PLoS One. 2010, 5 (2): e9201-","journal-title":"PLoS One"},{"issue":"22","key":"2921_CR14","first-page":"5276","volume":"55","author":"PE Andreotti","year":"1995","unstructured":"Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G, Gleiberman I, Caruso PA, Ricks SH, Untch M, Sartori C, Bruckner HW: Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res. 1995, 55 (22): 5276-5282.","journal-title":"Cancer Res"},{"key":"2921_CR15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/978-1-61779-080-5_21","volume":"731","author":"S Glaysher","year":"2011","unstructured":"Glaysher S, Cree IA: Cell sensitivity assays: the ATP-based tumor chemosensitivity assay. Methods Mol Biol. 2011, 731: 247-257.","journal-title":"Methods Mol Biol"},{"key":"2921_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzym Regul. 1984, 22: 27-55.","journal-title":"Adv Enzym Regul"},{"issue":"2","key":"2921_CR17","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0031-6997(25)06847-4","volume":"47","author":"WR Greco","year":"1995","unstructured":"Greco WR, Bravo G, Parsons JC: The search for synergy: a critical review from a response surface perspective. Pharmacol Rev. 1995, 47 (2): 331-385.","journal-title":"Pharmacol Rev"},{"key":"2921_CR18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/1471-2407-4-83","volume":"4","author":"LA Knight","year":"2004","unstructured":"Knight LA, Di Nicolantonio F, Whitehouse P, Mercer S, Sharma S, Glaysher S, Johnson P, Cree IA: The in vitro effect of gefitinib (\u2018Iressa\u2019) alone and in combination with cytotoxic chemotherapy on human solid tumours. BMC Cancer. 2004, 4: 83-","journal-title":"BMC Cancer"},{"issue":"37","key":"2921_CR19","doi-asserted-by":"publisher","first-page":"5193","DOI":"10.1038\/onc.2010.257","volume":"29","author":"A Chakrabarty","year":"2010","unstructured":"Chakrabarty A, Rexer BN, Wang SE, Cook RS, Engelman JA, Arteaga CL: H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3. Oncogene. 2010, 29 (37): 5193-5203.","journal-title":"Oncogene"},{"issue":"3","key":"2921_CR20","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1158\/2159-8290.CD-11-0085","volume":"1","author":"VS Rodrik-Outmezguine","year":"2011","unstructured":"Rodrik-Outmezguine VS, Chandarlapaty S, Pagano NC, Poulikakos PI, Scaltriti M, Moskatel E, Baselga J, Guichard S, Rosen N: mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov. 2011, 1 (3): 248-259.","journal-title":"Cancer Discov"},{"issue":"4","key":"2921_CR21","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1210\/me.2009-0328","volume":"24","author":"A Veilleux","year":"2010","unstructured":"Veilleux A, Houde VP, Bellmann K, Marette A: Chronic inhibition of the mTORC1\/S6K1 pathway increases insulin-induced PI3K activity but inhibits Akt2 and glucose transport stimulation in 3\u00a0T3-L1 adipocytes. Mol Endocrinol. 2010, 24 (4): 766-778.","journal-title":"Mol Endocrinol"},{"issue":"9","key":"2921_CR22","first-page":"3003","volume":"118","author":"S Grant","year":"2008","unstructured":"Grant S: Cotargeting survival signaling pathways in cancer. J Clin Invest. 2008, 118 (9): 3003-3006.","journal-title":"J Clin Invest"},{"issue":"7","key":"2921_CR23","first-page":"2609","volume":"118","author":"M Guix","year":"2008","unstructured":"Guix M, Faber AC, Wang SE, Olivares MG, Song Y, Qu S, Rinehart C, Seidel B, Yee D, Arteaga CL, Engelman JA: Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest. 2008, 118 (7): 2609-2619.","journal-title":"J Clin Invest"},{"issue":"Suppl 1","key":"2921_CR24","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1677\/erc.1.01275","volume":"13","author":"HE Jones","year":"2006","unstructured":"Jones HE, Gee JM, Hutcheson IR, Knowlden JM, Barrow D, Nicholson RI: Growth factor receptor interplay and resistance in cancer. Endocr Relat Cancer. 2006, 13 (Suppl 1): S45-S51.","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"2921_CR25","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/jcp.20588","volume":"207","author":"N Normanno","year":"2006","unstructured":"Normanno N, De Luca A, Maiello MR, Campiglio M, Napolitano M, Mancino M, Carotenuto A, Viglietto G, Menard S: The MEK\/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol. 2006, 207 (2): 420-427.","journal-title":"J Cell Physiol"},{"issue":"23","key":"2921_CR26","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1200\/JCO.2010.32.2321","volume":"29","author":"PK Morrow","year":"2011","unstructured":"Morrow PK, Wulf GM, Ensor J, Booser DJ, Moore JA, Flores PR, Xiong Y, Zhang S, Krop IE, Winer EP, Kindelberger DW, Coviello J, Sahin AA, Nunez R, Hortobagyi GN, Yu D, Esteva FJ: Phase I\/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol. 2011, 29 (23): 3126-3132.","journal-title":"J Clin Oncol"},{"issue":"Suppl 3","key":"2921_CR27","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.3816\/CBC.2010.s.015","volume":"10","author":"R Nahta","year":"2010","unstructured":"Nahta R, O\u2019Regan RM: Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K\/Akt\/mTOR pathway. Clin Breast Cancer. 2010, 10 (Suppl 3): S72-S78.","journal-title":"Clin Breast Cancer"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-0500-7-397.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T13:20:51Z","timestamp":1746278451000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/1756-0500-7-397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,25]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["2921"],"URL":"https:\/\/doi.org\/10.1186\/1756-0500-7-397","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,25]]},"assertion":[{"value":"8 July 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"397"}}